The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Source: View publication →
The IST-3 trial demonstrated that while intravenous alteplase administered within 6 hours of ischemic stroke did not significantly improve the primary outcome of functional independence at 6 months, it significantly improved the overall distribution of functional outcomes and confirmed safety in elderly populations.
Key Findings
Study Design
Study Limitations
Clinical Significance
IST-3 provided critical evidence expanding the therapeutic window for intravenous alteplase for acute ischemic stroke up to 6 hours, particularly supporting its use in elderly patients who were historically excluded from earlier thrombolysis trials. It underscores that while there is an early risk of symptomatic intracranial hemorrhage, the long-term functional benefits in the overall population and in high-risk subgroups justify its use within this extended timeframe.
Historical Context
Prior to IST-3, intravenous alteplase was primarily approved for use within a 3-hour window based on earlier trials (e.g., NINDS). The medical community remained divided over the risk-benefit ratio for patients treated between 3 and 6 hours and for patients aged over 80. By including a large, diverse population without an upper age limit, IST-3 provided the necessary robust data to justify expanding clinical practice guidelines to a 4.5-hour window.
Guided Discussion
High-yield insights from every perspective
Explain the biochemical mechanism by which recombinant tissue plasminogen activator (rt-PA) achieves reperfusion in acute ischemic stroke and why the 'time is brain' concept justifies the narrow 6-hour window studied in IST-3.
Key Response
Alteplase (rt-PA) binds to fibrin in a thrombus and converts trapped plasminogen to plasmin, which then degrades the fibrin matrix to dissolve the clot. The 6-hour window is based on the pathophysiology of the 'ischemic penumbra'—salvageable brain tissue surrounding the infarct core. As time progresses, the core expands and the risk of reperfusion injury and hemorrhagic transformation increases due to blood-brain barrier degradation.
The IST-3 trial included a large cohort of patients over age 80. How did the results for this subgroup challenge previous exclusion criteria for thrombolysis, and what was the trade-off regarding early versus late mortality?
Key Response
IST-3 demonstrated that patients over 80 actually derived at least as much benefit from alteplase as younger patients, despite being excluded from previous trials (like NINDS or ECASS). While there was an increased risk of early death (within 7 days) due to symptomatic intracranial hemorrhage (sICH) in the treated group, the 6-month functional outcomes showed an overall shift toward better recovery, suggesting that age alone should not be a contraindication to treatment.
The primary endpoint of IST-3 (Oxford Handicap Score 0-2 at 6 months) was not statistically significant, yet the study is often cited as a success. Critically evaluate the utility of the 'ordinal shift analysis' used in this trial compared to the traditional dichotomous outcome.
Key Response
Dichotomous outcomes (e.g., independent vs. dependent) often miss clinically meaningful improvements that occur within those categories. The ordinal shift analysis (looking at the entire distribution of the OHS) showed a significant benefit (p=0.016), suggesting that alteplase increases the odds of being in a better functional state across the whole spectrum of disability. For a fellow, this highlights that even if a patient doesn't achieve full independence, reducing the severity of their disability is a valuable therapeutic goal.
In the context of the IST-3 findings, how should a clinician approach the 'grey zone' of the 4.5 to 6-hour window for intravenous thrombolysis when mechanical thrombectomy is not immediately available?
Key Response
IST-3 provided the largest data set for the 4.5-6h window. While the absolute benefit is smaller and the risk of sICH is higher compared to earlier windows, the shift analysis suggests a persistent treatment effect. An attending must weigh the 'net' benefit: the trial showed that for every 1000 patients treated, roughly 28 more were alive and independent at 6 months despite the early risks. This necessitates nuanced shared decision-making regarding the increased risk of early fatal hemorrhage versus the chance of improved long-term function.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
IST-3 utilized a Prospective, Randomized, Open-label, Blinded-Endpoint (PROBE) design. Discuss how the lack of a placebo control might introduce 'performance bias' among treating clinicians and how this specifically complicates the interpretation of the 6-month functional outcomes.
Key Response
In an open-label study, clinicians know which patients received the drug. This could lead to differences in supportive care (co-interventions), such as more aggressive blood pressure management or earlier mobilization for the treatment group, which could confound functional recovery. While blinded outcome assessment (adjudicators unaware of treatment) reduces detection bias, it cannot fully account for the systematic differences in care that occur during the months following the initial intervention.
IST-3 failed to recruit its original target of 6,000 patients, finishing with approximately 3,000. Analyze how this reduction in sample size affects the trial's power to detect the primary endpoint and whether the subsequent emphasis on secondary ordinal analyses constitutes 'p-hacking' or a legitimate response to clinical complexity.
Key Response
The reduction in sample size increased the risk of a Type II error (false negative) for the primary endpoint. A journal editor would flag that while the shift analysis was pre-specified, the lack of significance in the primary outcome weakens the definitive nature of the trial. However, because the results were consistent with prior meta-analyses (like the SITS-MOST registry), the 'shift' is generally accepted as a valid reflection of biological effect rather than post-hoc data dredging.
Based on the IST-3 trial evidence, should current guidelines be updated to universally recommend IV alteplase up to 6 hours, and how does this compare to the 2018/2019 AHA/ASA recommendations for patients over 80?
Key Response
IST-3 was instrumental in moving the AHA/ASA guidelines to a Class I recommendation for IV alteplase in the 0-3 hour window for patients >80 (previously limited). However, for the 3-4.5 hour window in patients >80, it remains a Class IIb recommendation. Regarding the 6-hour window, guidelines remain conservative (typically recommending a 4.5-hour limit for IV tPA) because the benefit-to-risk ratio narrows significantly; current guidelines prioritize mechanical thrombectomy (up to 24h) for large vessel occlusions in the late window rather than extending the IV thrombolysis window for all comers.
Clinical Landscape
Noteworthy Related Trials
NINDS rt-PA Stroke Trial
Tested
IV rt-PA (alteplase)
Population
Patients with acute ischemic stroke
Comparator
Placebo
Endpoint
Favorable outcome at 3 months
ATLANTIS Trial
Tested
IV alteplase
Population
Patients with acute ischemic stroke in a 3- to 5-hour window
Comparator
Placebo
Endpoint
Excellent neurological recovery at 90 days
ECASS III Trial
Tested
IV alteplase
Population
Patients with acute ischemic stroke between 3 and 4.5 hours of symptom onset
Comparator
Placebo
Endpoint
Disability at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis